secwatch.observer — SEC 8-K summary
======================================

Issuer:     Journey Medical Corp (DERM)
CIK:        0001867066
Form:       8-K
Filed at:   2026-03-25T23:59:59+00:00
Accession:  0001104659-26-034506
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Journey Medical FY2025 revenue $61.9M (+10% YoY); net loss narrows to $11.4M
----------------------------------------------------------------------------

- Emrosi launch contributed $14.7M net revenue; ~53,000 prescriptions filled in FY2025.
- Gross margin improved to 66.2% from 62.8%, driven by higher-margin Emrosi and Qbrexza.
- Adjusted EBITDA positive $2.9M ($0.12 per diluted share) vs $0.8M in prior year.
- SG&A rose 10% to $44.4M due to Emrosi commercialization costs.
- Accutane revenue declined $6.5M amid competitive pressures.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1867066/000110465926034506/0001104659-26-034506-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1867066/000110465926034506/tm269707d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-034506

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer